0
0
CHANDIGARH — For decades, patients living with Type 2 diabetes in India have been conditioned to monitor three primary “microvascular” complications: damage to the eyes, kidneys, and nerves. However, a landmark nationwide study suggests it is time to add a fourth to that list.
The DiaFib-Liver Study, a massive screening initiative involving 9,202 adults across 27 hospitals and clinics in India, has revealed a startling trend: one in four Indian adults with Type 2 diabetes is living with clinically significant liver scarring (fibrosis). Perhaps most concerning is that this damage is frequently “silent,” progressing without symptoms until the liver reaches a state of failure.
Published in The Lancet Regional Health – Southeast Asia, the findings indicate that liver disease is no longer just a concern for heavy drinkers or those with viral hepatitis. Instead, carbohydrate-driven metabolic dysfunction is quietly fueling an epidemic of advanced liver disease across the subcontinent.
The “Fourth Major Complication”
The study represents the largest real-world survey of liver fibrosis in Type 2 diabetes ever conducted in a low- or middle-income country. The results paint a sobering picture of the current health landscape:
-
26% of participants had clinically significant liver fibrosis.
-
14% had progressed to advanced fibrosis stages.
-
5% showed markers suggestive of cirrhosis, a late-stage condition where healthy tissue is replaced by permanent scar tissue.
Researchers and clinicians are now calling for liver disease to be officially recognized as the “fourth major complication” of diabetes.
“Diabetes is the mother of modern liver disease,” says Dr. Ashish Kumar, a key investigator from the Ganga Ram Institute of Postgraduate Medical Education & Research (GRIPMER). He notes that in many Indian medical centers, diabetes-related liver damage now accounts for more transplants than traditional culprits like Hepatitis B or C.
Why the Liver Suffers in Diabetes
The link between the two conditions lies in how the body processes fuel. In Type 2 diabetes, persistently high blood sugar and insulin resistance cause fat to accumulate in the liver—a condition known as Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).
Over time, the liver becomes “hepatically insulin resistant.” It stops responding to the very hormone meant to regulate it, triggering a cascade of chronic inflammation and oxidative stress. This inflammation eventually leads to irreversible scarring, or fibrosis. If left unchecked, this scarring can evolve into liver failure or even liver cancer (hepatocellular carcinoma).
The “Lean-Patient Paradox”
One of the study’s most critical findings challenges the stereotype that liver disease only affects the obese. India faces a unique “lean-patient paradox,” where severe scarring occurs even in individuals with a “normal” Body Mass Index (BMI).
The data showed that 19% of patients with a BMI below 25 still suffered from clinically significant fibrosis. Researchers identified a pattern they call the “burnt-out” liver. In these cases, the fat that was once visible on an ultrasound disappears as the fibrosis worsens, leaving the organ shrunken and scarred rather than enlarged and fatty. For these patients, age and the cumulative “sugar load” over many years are better predictors of danger than body weight alone.
Closing the Screening Gap
Currently, routine diabetes care in India focuses heavily on HbA1c levels, foot exams, and kidney function tests. Liver assessment is rarely part of the standard protocol. When it is performed, doctors often rely on abdominal ultrasounds—a tool that is effective at spotting fat but frequently misses early-stage fibrosis or the “burnt-out” shrunken liver.
The DiaFib-Liver investigators advocate for a shift toward more precise, non-invasive diagnostic tools:
-
FIB-4 Score: A simple, low-cost calculation using a patient’s age and routine blood test results (platelet count, ALT, and AST).
-
FibroScan (VCTE): A specialized technology that measures liver stiffness through vibration, providing a direct “grade” of how much scarring is present.
International bodies, including the American Diabetes Association (ADA), already recommend using the FIB-4 score to screen high-risk groups. Experts urge Indian health authorities to integrate these tools into national primary-care protocols to catch damage before it becomes irreversible.
A Window for Reversal
While the findings are stark, they also offer a path toward prevention. Unlike advanced cirrhosis, early-stage liver fibrosis is often reversible.
“The liver has a remarkable capacity to heal if the metabolic pressure is removed,” explain experts associated with the study. Clinical data suggests:
-
A 5% weight loss can lead to the regression of fibrosis in up to 60% of patients.
-
A 10% weight loss may stabilize or even halt advanced fibrosis in nearly half of those affected.
Beyond lifestyle changes, newer classes of medications—such as GLP-1 receptor agonists and SGLT-2 inhibitors—which are already used to manage blood sugar, are showing promise in improving liver outcomes by reducing inflammation and fat storage.
Limitations and the Road Ahead
Despite its scale, the DiaFib-Liver Study has limitations. As a cross-sectional study, it provides a “snapshot” of the population rather than tracking disease progression over time. Additionally, because the data was collected primarily from hospital-based settings, it may not fully represent the liver health of rural populations who lack access to specialist care.
There is also ongoing debate regarding the best screening thresholds. Some hepatologists caution that universal screening might strain India’s healthcare infrastructure. Instead, they suggest a risk-stratified approach, prioritizing screening for those with long-standing diabetes, obesity, or existing kidney disease.
Public Health Implications
With approximately 101 million people living with diabetes in India and another 136 million with prediabetes, the potential burden of liver failure in the coming decades is staggering.
The DiaFib-Liver researchers argue that shifting the focus from reactive treatments (like costly liver transplants) to proactive screening (like the low-cost FIB-4) could save thousands of lives and billions in healthcare costs.
As global diabetes cases are projected to reach 780 million by 2045, India’s proactive stance on liver health could serve as a vital blueprint for the rest of the world.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://health.economictimes.indiatimes.com/news/industry/diabetes-emerges-as-a-major-driver-of-advanced-liver-disease-in-india/129943336?utm_source=top_story&utm_medium=homepage
